Naka R - Search Results

1

Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.

Naka R, Kondo T, Nishikubo M, Muranushi H, Ueda Y, Oka T, Wada F, Kanda J, Yamamoto S, Watanabe M, Okada S, Imada K, Nakabo Y, Mizutani Y, Nannya Y, Ogawa S, Ishikawa T. Naka R, et al. Am J Hematol. 2023 Sep;98(9):E251-E254. doi: 10.1002/ajh.27012. Epub 2023 Jun 28. Am J Hematol. 2023. PMID: 37381699 No abstract available.

2

Accumulation of free complex-type N-glycans in MKN7 and MKN45 stomach cancer cells.

Ishizuka A, Hashimto Y, Naka R, Kinoshita M, Kakehi K, Seino J, Funakoshi Y, Suzuki T, Kameyama A, Narimatsu H. Ishizuka A, et al. Among authors: naka r. Biochem J. 2008 Jul 15;413(2):227-37. doi: 10.1042/BJ20071562. Biochem J. 2008. PMID: 18399796

3

Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone).

Naka R, Tada K, Kaneko H, Nagata O, Tashima M, Mizutani C, Imada K. Naka R, et al. Leuk Lymphoma. 2022 Jun;63(6):1508-1511. doi: 10.1080/10428194.2022.2032040. Epub 2022 Feb 2. Leuk Lymphoma. 2022. PMID: 35105261 No abstract available.

4

Refractory immune thrombocytopenic purpura associated with IgM monoclonal gammopathy of undetermined significance: Successful treatment with tirabrutinib plus conventional therapies.

Naka R, Kaneko H, Nagata O, Tada K, Tashima M, Mizutani C, Imada K. Naka R, et al. EJHaem. 2022 Mar 17;3(2):513-516. doi: 10.1002/jha2.423. eCollection 2022 May. EJHaem. 2022. PMID: 35846034 Free PMC article.

5

Direct infiltration of clonal plasma cells causes renal insufficiency in patients with monoclonal gammopathy of undetermined significance.

Naka R, Shimomura Y, Kanda-Kato M, Hiramoto N, Hara S, Ishikawa T. Naka R, et al. EJHaem. 2023 Jun 26;4(3):829-832. doi: 10.1002/jha2.747. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601873 Free PMC article.

6

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.

Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H. Chuntova P, et al. Among authors: naka r. Neuro Oncol. 2022 Feb 1;24(2):259-272. doi: 10.1093/neuonc/noab182. Neuro Oncol. 2022. PMID: 34347086 Free PMC article.

7

Cell Wall-Denaturing Molecules for Plant Gene Modification.

Naka R, Tsuchiya K, Numata K. Naka R, et al. Chembiochem. 2023 Jun 15;24(12):e202200803. doi: 10.1002/cbic.202200803. Epub 2023 May 16. Chembiochem. 2023. PMID: 36811229 Review.

8

Caspase 3-specific cleavage of MEK1 suppresses ERK signaling and sensitizes cells to stress-induced apoptosis.

Moriizumi H, Kubota Y, Tsuchiya T, Naka R, Takekawa M. Moriizumi H, et al. Among authors: naka r. FEBS Open Bio. 2023 Apr;13(4):684-700. doi: 10.1002/2211-5463.13574. Epub 2023 Feb 23. FEBS Open Bio. 2023. PMID: 36776127 Free PMC article.

9

Gendered Trajectories to Tolerance: Men's and Women's Changing Attitudes toward Homosexuality in Japan, 1981-2019.

Naka R. Naka R. J Homosex. 2023 Dec 6;70(14):3493-3514. doi: 10.1080/00918369.2022.2095243. Epub 2022 Jul 20. J Homosex. 2023. PMID: 35856608

10

Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.

Kubota Y, Fujioka Y, Patil A, Takagi Y, Matsubara D, Iijima M, Momose I, Naka R, Nakai K, Noda NN, Takekawa M. Kubota Y, et al. Among authors: naka r. Nat Commun. 2022 Jul 13;13(1):4063. doi: 10.1038/s41467-022-31690-w. Nat Commun. 2022. PMID: 35831322 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page